lung cancer gene and literature database Home
Cancer metastasis database

Annotation category 5

Literatures

Literature evidence

Links to all GeneRIF Items

2922

PubMed (Gene Name)

Literature evidence

12474049 (GRP)

mRNA transcripts are expressed in tumor cells of patients with small cell lung cancer

12820318 (GRP)

ProGRP is a valuable tumour marker for the detection and monitoring of small cell lung cancer (SCLC) and a good tool for discriminating non-small cell lung cancer (NSCLC) versus SCLC

12820319 (GRP)

results show that Pro-GRP may be a potential tumor marker for small cell lung carcinoma

15638385 (GRP)

Measuring serum levels in lung cancer patients may be useful in drug therapy monitoring.

19506400 (GRP)

tumor marker determination, incluidng ProGRP, in patients with suspicious signs of lung cancer suggests, in a few hours, the histological diagnosis in the majority of lung cancer patients.

21529988 (GRP)

serum-positive non-small-cell lung cancers may have neuroendocrine differentiation

24375395 (GRP)

High serum proGRP levels are associated with small-cell lung cancer.

26560853 (GRP)

CEA, NSE, CA125 and pro-GRP could serve as biomarkers for SCLC, and CEA and CYFRA21-1 could serve as biomarkers for NSCLC. Pro-GRP, CA125 and CEA were related to the clinical stages of lung cancer

26886220 (GRP)

High proGRP expression is associated with poor response to chemotherapy in small cell lung cancer.

27639644 (GRP)

pro-gastrin releasing peptide has a role in promoting the cell proliferation and progression in small cell lung cancer

28351312 (GRP)

Our results suggest that, similar to what happens in neutrophils, gastrin-releasing peptide is a migratory, rather than a proliferative, stimulus, for non-small cell lung carcinoma cells, indicating a putative role for gastrin-releasing peptide and gastrin-releasing peptide receptor in metastasis

29145241 (GRP)

serum level not a biomarker in small cell lung cancer

29729229 (GRP)

A panel of three tumor markers CYFRA 21.1, HE4 and ProGRP may play a role for discriminating LC from benign lung disease and subtyping as SCLC.

29989303 (GRP)

ProGRP and NSE serum expression levels predict therapeutic drug response in Chinese lung cancer patients.

30146822 (GRP)

The serum pro-gastrin-releasing peptide (ProGRP) levels were increased in a variety of benign and malignant diseases and were considered a putative marker for small cell lung cancer (SCLC).

31091854 (GRP)

Studied association of progastrin-releasing peptide (proGRP), neuron specific enolase (NSE), chromogranin a (CgA), and squamous cell cancer antigen (SCCA1) in pulmonary neuroendocrine tumor (PNET) and non-small-cell lung carcinoma (NSCLC). Results showed ProGRP can distinguish PNET patients from NSCLC patients, and with adjusted NSE values, it can differentiate the PNET group from the benign disease group.